Non-originator biologicals approved in Russia

Biosimilares/General | Posted 10/01/2020 post-comment0 Post your comment

Last update: 10 January 2020

In Russia, the regulatory body for the approval of medicines is Russia’s Ministry of Health (Министерство здравоохранения Российской Федерации; Rosminzdrav, Minzdrav).

Russia V20A10

The Ministry of Health coordinates and oversees the operation of its subordinated services and agencies, including the Federal Supervision Service for Healthcare, the Federal Medical-Biological Agency, federal state institutions and unitary enterprises; and coordinates the work of the Federal Mandatory Health Insurance Fund.

Although Russia has a strong generics market, it has not yet developed a regulatory framework for biologicals or biosimilars. In fact, Russia has yet to define what a biosimilar is, and Russian Law does not yet recognize biosimilars as distinct products [1].

The first non-originator biological to receive approval in Russia was Biocad’s multiple sclerosis treatment Interferon beta-1b (BCD-033) in 2009. To date, Minzdrav has approved eight non-originator biologicals within the product classes of human growth hormone, granulocyte colony-stimulating factor (G-CSF), monoclonal antibodies and tumour necrosis factor (TNF)-inhibitor, for use in Russia, see Table 1.

Table 1: Minzdrav approved non-originator biologicals*
Company name, Country Active substance Therapeutic area Authorization date Manufacturer/ Company name
Acellbia (BCD-020) rituximab Chronic lymphocytic leukaemia
Granulomatosis with polyangiitis
Microscopic polyangiitis
Non-Hodgkin’s lymphoma
Rheumatoid arthritis
17 Apr 2014 Biocad
Avegra (BCD-021) bevacizumab Breast cancer
Cervical cancer
Colorectal cancer
Lung cancer
Ovarian cancer
Renal cell cancer
30 Nov 2015 Biocad
Elizaria eculizumab Paroxysmal nocturnal haemoglobinuria
Atypical haemolytic uremic syndrome
9 Apr 2019 Generium
Flammegis infliximab Ankylosing spondylitis
Crohn’s disease
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Jul 2015 Celltrion
Herticad (BCD-022) trastuzumab Early breast cancer
Metastatic breast cancer
Metastatic gastric cancer
20 Jan 2016 Biocad
Infliximab (BCD-055) infliximab Ankylosing spondylitis
Crohn’s disease
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Feb 2018 Biocad
Rebif (BCD‑033) interferon beta-1b Multiple sclerosis 3 Mar 2009 Biocad
Remsima infliximab Crohn’s disease#
Ankylosing spondylitis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis#
13 Jul 2015 Celltrion
*Data collected on 12 December 2019.
Source: Mindraz

Editor’s comment
It should be noted that ‘non-originator biologicals’ approved in Russia might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related article
Biosimilars approved in Europe

1.  GaBI Online - Generics and Biosimilars Initiative. Russia to harmonize biologicals regulations []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jan 10]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: Mindraz

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010